论文部分内容阅读
目的:观察培美曲塞单药二线治疗晚期复发或进展非小细胞肺癌的临床疗效及不良反应。方法:经病理学或细胞学确诊、一线化疗后出现复发或进展的晚期非小细胞肺癌患者50例,治疗方案为培美曲塞二钠500mg·m-2,第1天给药,21d为1个周期,完成2个周期以上化疗后评价疗效和不良反应。结果:治疗有效率为8.0%(4/50),疾病控制率为76.0%(38/50),1年生存率为55.3%(26/47),中位生存期为12.5个月,中位无进展生存期为2.1个月。主要不良反应为肝功能损伤、皮疹、骨髓抑制。结论:培美曲塞单药二线治疗晚期非小细胞肺癌疗效较好,不良反应较轻。
Objective: To observe the clinical efficacy and adverse reactions of pemetrexed monotherapy in second-line treatment of advanced recurrent or advanced non-small cell lung cancer. Methods: Fifty patients with advanced non-small cell lung cancer who had recurred or advanced after first-line chemotherapy were diagnosed by pathology or cytology. The treatment regimen was pemetrexed disodium 500 mg · m-2, administered on the first day, and on the 21st day 1 cycle, completed more than 2 cycles after chemotherapy evaluation of efficacy and adverse reactions. Results: The effective rate was 8.0% (4/50), the disease control rate was 76.0% (38/50), the 1-year survival rate was 55.3% (26/47) and the median survival time was 12.5 months Progression free survival was 2.1 months. The main adverse reactions were liver damage, rash and myelosuppression. Conclusion: Pemetrexed monotherapy second-line treatment of advanced non-small cell lung cancer better efficacy, less adverse reactions.